Ocular inserts for sustained release of the angiotensin-converting enzyme 2 activator, diminazene aceturate, to treat glaucoma in rats

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Foureaux, Giselle ^a   Franca, Juçara Ribeiro ^a   Nogueira, José Carlos ^a   De Oliveira Fulgêncio, Gustavo ^a   Ribeiro, Tatiana Gomes ^a   Castilho, Rachel Oliveira ^a   Yoshida, Maria Irene ^a   Fuscaldi, Leonardo Lima ^a   Fernandes, Simone Odília Antunes ^a   Cardoso, Valbert Nascimento ^a   Cronemberger, Sebastião ^a   Faraco, André Augusto Gomes ^a   Ferreira, Anderson José ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CHITOSAN; DIMINAZENE ACETURATE; ANGIOTENSIN CONVERTING ENZYME 2; DELAYED RELEASE FORMULATION; DIMINAZENE; DIPEPTIDYL CARBOXYPEPTIDASE; EYE PROTEIN; HYALURONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTERIOR EYE CHAMBER; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG SYNTHESIS; GLAUCOMA; HISTOPATHOLOGY; IN VITRO STUDY; INFRARED SPECTROSCOPY; INTRAOCULAR PRESSURE; MALE; NEUROPROTECTION; NONHUMAN; OPTIC NERVE; PROCESS DEVELOPMENT; RAT; RETINA GANGLION CELL; SUSTAINED DRUG RELEASE; SWELLING; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD PRESSURE; CHEMICALLY INDUCED; DELAYED RELEASE FORMULATION; DRUG EFFECTS; ENZYME ACTIVATION; INTRAOCULAR DRUG ADMINISTRATION; PATHOLOGY; PRECLINICAL STUDY; SCANNING ELECTRON MICROSCOPY; TISSUE DISTRIBUTION; WISTAR RAT;

ADMINISTRATION, OPHTHALMIC; ANIMALS; BLOOD PRESSURE; CALORIMETRY, DIFFERENTIAL SCANNING; CHITOSAN; DELAYED-ACTION PREPARATIONS; DIMINAZENE; DRUG EVALUATION, PRECLINICAL; ENZYME ACTIVATION; EYE PROTEINS; GLAUCOMA; HYALURONIC ACID; INTRAOCULAR PRESSURE; MALE; MICROSCOPY, ELECTRON, SCANNING; PEPTIDYL-DIPEPTIDASE A; RATS; RATS, WISTAR; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TISSUE DISTRIBUTION;

EID: 84941702318     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0133149     Document Type: Article

References (61)

1. Weinreb RN, Tee Khaw P. Primary open-angle glaucoma. Lancet. 2004;363:1711-1720. PMID: 15158634
2. Almasieh M, Wilson AM, Morquette B, Cueva Vargas JL, Di Polo A. The molecular basis of retinal ganglion cell death in glaucoma. Progress in Retinal and Eye Research. 2012;31:152-181. doi: 10.1016/j.preteyeres.2011.11.002 PMID: 22155051
3. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. British Journal of Ophthalmology. 2006;90:262-267. PMID: 16488940
4. Costa VP, Harris A, Stefánsson E, Flammer J, Krieglstein GK, Orzalesi N, et al. The effects of antiglaucoma and systemic medications on ocular blood flow. Progress in Retinal and Eye Research. 2003;22:769-805. PMID: 14575724
5. Gulsen D, Chauhan A. Dispersion of microemulsion drops in HEMA hydrogel: a potential ophthalmic drug delivery vehicle. International Journal of Pharmaceutics. 2005;292:95-117. PMID: 15725557
6. Ludwig A. The use of mucoadhesive polymers in ocular drug delivery. Advanced Drug Delivery Reviews. 2005;57:1595-1639. PMID: 16198021
7. Ghate D, Edelhauser HF. Barriers to glaucoma drug delivery. Journal of Glaucoma. 2008;17:147-156. doi: 10.1097/IJG.0b013e31814b990d PMID: 18344762
8. Aggarwal D, Kaur IP. Improved pharmacodynamics of timolol maleate from a mucoadhesive niosomal ophthalmic drug delivery system. International Journal of Pharmaceutics. 2005;290:155-159. PMID: 15664141
9. Lee SS, Hughes P, Ross AD, Robinson MR. Biodegradable Implants for Sustained Drug Release in the Eye. Pharmaceutical Research. 2010;27:2043-2053. doi: 10.1007/s11095-010-0159-x PMID: 20535532
10. Kearns VR, Williams RL. Drug delivery systems for the eye. Expert Review of Medical Devices. 2009;6:277-290. doi: 10.1586/erd.09.4 PMID: 19419285
11. Aburahma MH, Mahmoud AA. Biodegradable Ocular Inserts for Sustained Delivery of Brimonidine Tartarate: Preparation and In Vitro/In Vivo Evaluation. Aaps Pharmscitech. 2011;12:1335-1347. doi: 10. 1208/s12249-011-9701-3 PMID: 21979886
12. Chen RH, Lin JH, Yang MH. Relationships between the chain flexibilities of chitosan molecules and the physical-properties of their casted films. Carbohydrate Polymers. 1994;24:41-46.
13. Zambito Y, Di Colo G. Chitosan and its derivatives as intraocular penetration enhancers. Journal of Drug Delivery Science and Technology. 2010;20:45-52.
14. Ferrario CM. The renin-angiotensin system: Importance in physiology and pathology. Journal of Cardiovascular Pharmacology. 1990;15:S1-S5.
15. Ferrario CM. Angiotensin-converting enzyme 2 and angiotensin-(1-7): an evolving story in cardiovascular regulation. Hypertension. 2006;47:515-521. PMID: 16365192
16. Danser A H J, Derkx F H M, Admiraal P J J, Deinum J, De Jong P T VM, Schalekamp M A DH. Angiotensin levels in the eye. Investigative Ophthalmology and Visual Science. 1994;35:1008-1018. PMID: 8125711
17. Wagner J, Danser A H J, Derkx F H M, De Jong P T VM, Paul M, Mullins JJ, et al. Demonstration of renin mRNA, angiotensinogen mRNA, and angiotensin converting enzyme mRNA expression in the human eye: Evidence for an intraocular renin-angiotensin system. British Journal of Ophthalmology. 1996;80:159-163. PMID: 8814748
18. Ramirez M, Davidson EA, Luttenauer L, Elena PP, Cumin F, Mathis GA, et al. The renin-angiotensin system in the rabbit eye. Journal of Ocular Pharmacology and Therapeutics. 1996;12:299-312. PMID: 8875336
19. Luhtala S, Vaajanen A, Oksala O, Valjakka J, Vapaatalo H. Activities of Angiotensin-Converting Enzymes ACE1 and ACE2 and Inhibition by Bioactive Peptides in Porcine Ocular Tissues. Journal of Ocular Pharmacology and Therapeutics. 2009;25:23-28. doi: 10.1089/jop. 2008.0081 PMID: 19232015
20. Vaajanen A, Lakkisto P, Virtanen I, Kankuri E, Oksala O, Vapaatalo H, et al. Angiotensin receptors in the eyes of arterial hypertensive rats. Acta Ophthalmologica. 2009;88:431-438. doi: 10.1111/j.1755-3768.2009.01563.x PMID: 19758401
21. Schindler C, Bramlage P, Kirch W, Ferrario CM. Role of the vasodilator peptide angiotensin-(1-7) in cardiovascular drug therapy. Vascular Health and Risk Management. 2007;3:125-137. PMID: 17583183
22. Santos R A S, Ferreira AJ, Simões E Silva AC. Recent advances in the angiotensin-converting enzyme 2-angiotensin (1-7)-Mas axis. Experimental Physiology. 2008;93:519-527. doi: 10.1113/expphysiol. 2008.042002 PMID: 18310257
23. Ferreira AJ, Santos R A S, Bradford CN, Mecca AP, Sumners C, Katovich MJ, et al. Therapeutic implications of the vasoprotective axis of the renin-angiotensin system in cardiovascular diseases. Hypertension. 2010;55:207-213. doi: 10.1161/HYPERTENSIONAHA.109.140145 PMID: 20038757
24. Ferreira AJ, Shenoy V, Qi Y, Fraga-Silva RA, Santos RA, Katovich MJ, et al. Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signalregulated kinases. Experimental Physiology. 2011;96:287-294. doi: 10.1113/expphysiol.2010. 055277 PMID: 21148624
25. Ferreira AJ, Bader M, Santos R A S. Therapeutic targeting of the angiotensin-converting enzyme 2/Angiotensin-(1-7)/Mas cascade in the reninangiotensin system: A patent review. Expert Opinion on Therapeutic Patents. 2012;22:567-574. doi: 10.1517/13543776.2012.682572 PMID: 22510001
26. Foureaux G, Nogueira JC, Nogueira BS, Fulgencio GO, Menezes GB, Fernandes SO, et al. Antiglaucomatous effects of the activation of intrinsic Angiotensin-converting enzyme 2. Investigative ophthalmology & visual science. 2013;54:4296-4306.
27. Rodrigues LB, Leite HF, Yoshida MI, Saliba JB, Cunha AS, Faraco A A G. In vitro release and characterization of chitosan films as dexamethasone carrier. International Journal of Pharmaceutics. 2009;368:1-6. doi: 10.1016/j.ijpharm.2008.09.047 PMID: 18955123
28. Natu MV, Gaspar MN, Fontes Ribeiro CA, Cabrita AM, De Sousa HC, Gil MH. In vitro and in vivo evaluation of an intraocular implant for glaucoma treatment. International journal of pharmaceutics. 2011;415:73-82. doi: 10.1016/j.ijpharm.2011.05.047 PMID: 21641984
29. Perumal VA, Lutchman D, Mackraj I, Govender T. Formulation of monolayered films with drug and polymers of opposing solubilities. International Journal of Pharmaceutics. 2008;358:184-191. doi: 10. 1016/j.ijpharm.2008.03.005 PMID: 18430529
30. Eroglu H, Sargon MF, Oener L. Chitosan formulations for steroid delivery: Effect of formulation variables on in vitro characteristics. Drug Development and Industrial Pharmacy. 2007;33:265-271. PMID: 17454059
31. Dobaria NB, Badhan AC, Mashru RC. A Novel Itraconazole Bioadhesive Film for Vaginal Delivery: Design, Optimization, and Physicodynamic Characterization. Aaps Pharmscitech. 2009;10:951-959. doi: 10.1208/s12249-009-9288-0 PMID: 19629707
32. Baranowski P, Karolewicz B, Gajda M, Pluta J. Ophthalmic drug dosage forms: characterisation and research methods. The Scientific World Journal. 2014;2014:861904. doi: 10.1155/2014/861904 PMID: 24772038
33. Moreno MC, Aldana Marcos HJ, Croxatto JO, Sande PH, Campanelli J, Jaliffa CO, et al. A new experimental model of glaucoma in rats through intracameral injections of hyaluronic acid. Experimental eye research. 2005;81:71-80. PMID: 15978257
34. Peng CC, Burke MT, Carbia BE, Plummer C, Chauhan A. Extended drug delivery by contact lenses for glaucoma therapy. Journal of Controlled Release. 2012;162:152-158. doi: 10.1016/j.jconrel.2012.06. 017 PMID: 22721817
35. Rodrigues LB, Leite HF, Yoshida MI, Saliba JB, Cunha AS Jr., Faraco AA. In vitro release and characterization of chitosan films as dexamethasone carrier. International journal of pharmaceutics. 2009;368:1-6. doi: 10.1016/j.ijpharm.2008.09.047 PMID: 18955123
36. Moradi M, Yamini Y, Rezaei F, Tahmasebi E, Esrafili A. Development of a new and environment friendly hollow fiber-supported liquid phase microextraction using vesicular aggregate-based supramolecular solvent. The Analyst. 2012;137:3549-3557. doi: 10.1039/c2an35304k PMID: 22733347
37. Olbrich C, Gessner A, Kayser O, Muller RH. Lipid-drug-conjugate (LDC) nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug diminazenediaceturate. Journal of drug targeting. 2002;10:387-396. PMID: 12442809
38. Soliman GM, Winnik FM. Enhancement of hydrophilic drug loading and release characteristics through micellization with new carboxymethyldextran-PEG block copolymers of tunable charge density. International journal of pharmaceutics. 2008;356:248-258. doi: 10.1016/j.ijpharm.2007.12.029 PMID: 18242897
39. Bourlais CL, Acar L, Zia H, Sado PA, Needham T, Leverge R. Ophthalmic drug delivery systems-recent advances. Progress in Retinal and Eye Research. 1998;17:33-58. PMID: 9537794
40. Shah GB, Sharma S, Mehta AA, Goyal RK. Oculohypotensive effect of angiotensin-converting enzyme inhibitors in acute and chronic models of glaucoma. Journal of Cardiovascular Pharmacology. 2000;36:169-175. PMID: 10942157
41. Wang R-F, Podos SM, Mittag TW, Yokoyoma T. Effect of CS-088, an angiotensin AT1 receptor antagonist, on intraocular pressure in glaucomatous monkey eyes. Experimental eye research. 2005;80:629-632. PMID: 15862169
42. Loftsson T, Thorisdóttir S, Fridriksdóttir H, Stefánsson E. Enalaprilat and enalapril maleate eyedrops lower intraocular pressure in rabbits. Acta Ophthalmologica. 2010;88:337-341. doi: 10.1111/j.1755-3768.2008.01495.x PMID: 19432862
43. Constad WH, Fiore P, Samson C, Cinotti AA. Use of an angiotensin converting enzyme inhibitor in ocular hypertension and primary open-angle glaucoma. American Journal of Ophthalmology. 1988;105:674-677. PMID: 3287943
44. Costagliola C, Di Benedetto R, De Caprio L, Verde R, Mastropasqua L. Effect of oral captopril (SQ 14225) on intraocular pressure in man. European Journal of Ophthalmology. 1995;5:19-25. PMID: 7795397
45. Costagliola C, Verolino M, De Rosa ML, Iaccarino G, Ciancaglini M, Mastropasqua L. Effect of oral losartan potassium administration on intraocular pressure in normotensive and glaucomatous human subjects. Experimental eye research. 2000;71:167-171. PMID: 10930321
46. Qiu Y, Shil PK, Zhu P, Yang H, Verma A, Lei B, et al. Angiotensin-converting enzyme 2 (ACE2) activator diminazene aceturate ameliorates endotoxin-induced uveitis in mice. Investigative ophthalmology & visual science. 2014;55:3809-3818.
47. Senanayake Pd, Drazba J, Shadrach K, Milsted A, Rungger-Brandle E, Nishiyama K, et al. Angiotensin II and Its Receptor Subtypes in the Human Retina. Investigative ophthalmology & visual science. 2007;48:3301-3311.
48. Tikellis C, Johnston CI, Forbes JM, Burns WC, Thomas MC, Lew RA, et al. Identification of angiotensin converting enzyme 2 in the rodent retina. Current Eye Research. 2004;29:419-427. PMID: 15764086
49. Kulemina LV, Ostrov DA. Prediction of Off-Target Effects on Angiotensin-Converting Enzyme 2. Journal of Biomolecular Screening. 2011;16:878-885. doi: 10.1177/1087057111413919 PMID: 21859683
50. Nathanson JA, McKee M. Identification of an extensive system of nitric oxide-producing cells in the ciliary muscle and outflow pathway of the human eye. Investigative Ophthalmology and Visual Science. 1995;36:1765-1773. PMID: 7543462
51. Santos R A S, Campagnole-Santos MJ, Andrade SP. Angiotensin-(1-7): An update. Regulatory Peptides. 2000;91:45-62. PMID: 10967201
52. Kostenis E, Milligan G, Christopoulos A, Sanchez-Ferrer CF, Heringer-Walther S, Sexton PM, et al. Gproteincoupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor. Circulation. 2005;111:1806-1813. PMID: 15809376
53. Neufeld AH. Nitric oxide: A potential mediator of retinal ganglion cell damage in glaucoma. Survey of Ophthalmology. 1999;43:S129-S135. PMID: 10416755
54. Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Egido J. Inflammation and angiotensin II. The international journal of biochemistry & cell biology. 2003;35:881-900.
55. Kaufman PL, Calkins BT, Erickson KA. Ocular biometry of the cynomolgus monkey. Current Eye Research. 1981;1(5):307-309. PMID: 7307539
56. Inoue T, Yokoyoma T, Koike H. The effect of angiotensin II on uveoscleral outflow in rabbits. Current Eye Research. 2001;23(2):139-143. PMID: 11840353
57. Hashizume K, Mashima Y, Fumayama T, Othake Y, Kimura I, Yoshida K et al. Genetic polymorphisms in the angiotensin II receptor gene and their association with open-angle glaucoma in a Japanese population. Investigative Ophthalmology and Visual Science. 2005;46(6):1993-2001. PMID: 15914614
58. Murça TM, Moraes PL, Capuruco CA, Santos S H S, Melo MB, Santos R A S et al. Oral administration of an angiotensin-converting enzyme 2 activator ameliorates diabetes-induced cardiac dysfunction. Regulatory Peptides. 2012;177(1-3):107-115. doi: 10.1016/j.regpep. 2012.05.093 PMID: 22595130
59. Vaajanen A, Vapaatalo H. Local ocular renin-angiotensin system-a target for glaucoma therapy? Basic & Clinical Pharmacology & Toxicology. 2011;109:217-224.
60. Lotti VJ, Pawlowski N. Prostaglandins mediate the ocular hypotensive action of the angiotensin converting enzyme inhibitor MK-422 (enalaprilat) in African green monkeys. Journal of Ocular Pharmacology. 1990;6(1):1-7. PMID: 2163428
61. Kuntner C, Wanek T, Hoffer M, Dangl D, Hornof M, Kvaternik H, et al. Radiosynthesis and assessment of ocular pharmacokinetics of (124) I-labeled chitosan in rabbits using small-animal PET. Molecular imaging and biology: MIB: the official publication of the Academy of Molecular Imaging. 2011;13:222-226.